First in human Phase I study - results of a second-generation non-ansamycin heat shock protein 90 (HSP90) inhibitor AT13387 in refractory solid tumors
Phase I study assessing a two-consecutive-day (QD x 2) dosing schedule of the HSP90 inhibitor, AT13387, in patients with advanced solid tumors
A Phase I trial of AT9283 (a selective inhibitor of Aurora kinases) given for 72 hours every 21 days via intravenous infusion in children and adolescents with relapsed and refractory solid tumors
Select posters will be made available for viewing on the company's website www.astx.com following the public presentation.
For more information about
Timothy L. Enns Astex Pharmaceuticals, Inc.Senior Vice President Corporate Communications & MarketingTel: (925) 560-2810 E-mail: email@example.com Susanna Chau Astex Pharmaceuticals, Inc.Manager Investor Relations Tel: (925) 560-2845 E-mail: firstname.lastname@example.org Alan Roemer The Trout GroupManaging Director Tel: (646) 378-2945 E-mail: email@example.com Melanie Toyne-Sewell( Europe) Rebecca Skye Dietrich(US) College Hill Tel: +44 20 7866 7866 Tel: (857) 241-0795 E-mail: firstname.lastname@example.org
News Provided by Acquire Media